NAYA Biosciences, Inc. Common Stock
NAYA Biosciences, Inc. Common Stock (IVF) Financial Performance & Income Statement Overview
Analyze NAYA Biosciences, Inc. Common Stock (IVF) financial statements (income, balance sheet, and cash flow) across both yearly and quarterly periods.
NAYA Biosciences, Inc. Common Stock (IVF) Income Statement & Financial Overview
Access detailed annual and quarterly income data for NAYA Biosciences, Inc. Common Stock IVF financial performance.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $1.69M | $1.43M | $1.84M | $1.58M |
| Cost of Revenue | $957419.00 | $988465.00 | $861648.00 | $850234.00 |
| Gross Profit | $728547.00 | $444686.00 | $974949.00 | $726052.00 |
| Gross Profit Ratio | $0.43 | $0.31 | $0.53 | $0.46 |
| R&D Expenses | $484780.00 | $0.00 | $0.00 | $4880.00 |
| SG&A Expenses | $3.48M | $1.51M | $2.65M | $1.44M |
| Operating Expenses | $4.70M | $1.75M | $2.88M | $1.67M |
| Total Costs & Expenses | $5.66M | $2.73M | $3.74M | $2.52M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $231824.00 | $273629.00 | $369612.00 | $181295.00 |
| Depreciation & Amortization | $231810.00 | $230495.00 | $230338.00 | $226960.00 |
| EBITDA | -$3.21M | -$1.10M | -$1.65M | -$1.19M |
| EBITDA Ratio | -$1.91 | -$0.77 | -$0.90 | -$0.75 |
| Operating Income | -$3.98M | -$1.30M | -$1.90M | -$946374.00 |
| Operating Income Ratio | -$2.36 | -$0.91 | -$1.04 | -$0.60 |
| Other Income/Expenses (Net) | $298306.00 | -$301001.00 | -$342257.00 | -$648303.00 |
| Income Before Tax | -$3.68M | -$1.60M | -$2.25M | -$1.59M |
| Income Before Tax Ratio | -$2.18 | -$1.12 | -$1.22 | -$1.01 |
| Income Tax Expense | -$54008.00 | $29259.00 | $0.00 | $1836.00 |
| Net Income | -$3.62M | -$1.63M | -$2.25M | -$1.60M |
| Net Income Ratio | -$2.15 | -$1.14 | -$1.22 | -$1.01 |
| EPS | -$9.04 | -$5.04 | -$7.44 | -$5.04 |
| Diluted EPS | -$9.04 | -$5.04 | -$7.44 | -$5.04 |
| Weighted Avg Shares Outstanding | $401011.00 | $323832.00 | $300817.00 | $316823.00 |
| Weighted Avg Shares Outstanding (Diluted) | $401011.00 | $323832.00 | $300817.00 | $316823.00 |
The company's financials show resilient growth, with revenue advancing from $1.58M in Q1 2024 to $1.69M in Q4 2024. Gross profit remained healthy with margins at 43% in Q4 2024 compared to 46% in Q1 2024. Operating income hit -$3.98M last quarter, sustaining a consistent -236% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at -$3.21M. Net income dropped to -$3.62M, while earnings per share reached -$9.04. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan